Slide 1: Integer Holdings Corporation First Quarter 2026 Earnings Conference Call
Integer Holdings Corporation (ITGR) First Quarter 2026 Earnings Conference Call April 30, 2026 ITGR: 1Q26 Earnings Conference Call April 30, 2026 | 1
Slide 2: Presenters and Agenda
Presenters and Agenda Today’s agenda: Payman Khales President, Chief Executive Officer • Opening Remarks • Financial Results Diron Smith Executive Vice President, • Financial Outlook Chief Financial Officer • Wrap-up • Q&A Kristen Stewart, CFA Director, Investor Relations ITGR: 1Q26 Earnings Confere
Slide 3: Presentation of Financial Information & Forward-Looking Statements
Presentation of Financial Information & Forward-Looking Statements Important Information This presentation contains summarized information concerning Integer Holdings Corporation (the “Company”) and its business, operations, financial performance and trends. The historical financial and operating da
Slide 4: Opening Remarks
Opening Remarks ITGR: 1Q26 Earnings Conference Call April 30, 2026 | 4
Slide 5: Summary
Summary 1Q organic sales up 1%, in 1Q26 financial results in line with February outlook line with February outlook • Organic sales up 1% versus the prior year, impacted primarily by expected headwinds from the three new products • Adjusted operating income margin declined 230bps, driven primarily by
Slide 6: Financial Results
Financial Results O Integer’
Slide 7: 1Q26 Financial Results
1Q26 Financial Results ($ in millions, except per share amounts) Sales Adj. EBITDA Adj. Operating Income Adj. Net Income Adj. EPS Change 0.5% (7)% (14)% (10)% (8)% Organic 1.3% $437 $440 $92 $85 $71 $61 $46 $1.31 $41 $1.20 1Q25 1Q26 1Q25 1Q26 1Q25 1Q26 1Q25 1Q26 1Q25 1Q26 Organic sales change, adjus
Slide 8: Cardio & Vascular
(1) % of Sales Cardio & Vascular ($ in millions) 60% Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the development and manufacturing of complex components, sub-assemblies, and finished devices Quarte
Slide 9: Cardiac Rhythm Management & Neuromodulation (CRM&N)
(1) % of Sales Cardiac Rhythm Management & Neuromodulation (CRM&N) ($ in millions) 36%59% Providing technology solutions for the active implantable medical device industry by partnering with customers to bring high-quality products to established and emerging markets – from initial concept through h
Slide 10: 1Q26 Adjusted Net Income and EPS
1Q26 Adjusted Net Income and EPS ($ in millions, except per share amounts) Adj. Net Income Adjusted net income, adjusted EPS, adjusted interest expense, adjusted effective tax rate, and adjusted weighted average shares are non-GAAP financial measures; refer to “Non- ITGR: 1Q26 Earnings Conference Ca
Slide 11: Cash Flow and Leverage Trends
Cash Flow and Leverage Trends ($ in millions) Cash Flow From Ops Free Cash Flow Net Total Debt CAPEX Leverage $25 $27 $24 3.3x $19 $19 3.2x 3.0x 3.0x 3.2x $1,230 $1,264 $1,204 $1,190 $1,158 $66 $55 $44 $46 $31 $25 $28 $25 $6 $1 1Q25 2Q25 3Q25 4Q25 1Q26 1Q25 2Q25 3Q25 4Q25 1Q26 1Q25 2Q25 3Q25 4Q25 1Q
Slide 12: Financial Outlook
Financial Outlook O Integer’
Slide 13: 2026 Financial Outlook
2026 Financial Outlook ($ in millions, except per share amounts) Sales Adj. EBITDA Adj. Operating Income Adj. Net Income Adj. EPS Change (3)% - (1)% (7)% - (1)% (11)% - (5)% (11)% - (3)% (9)% - 0% Organic (1)% - 0% $1,854 $1,805 - $1,835 $402 $375 - $399 $321 $285 - $305 $226 $6.40 $200 - $220 $5.83
Slide 14: 2026 Financial Outlook
2026 Financial Outlook ($ in millions) 2026 Sales Outlook • Organic sales flat to down 1%; Reported sales down 1% to 3% 3% - 4% 2026 Product Line Sales Outlook • C&V sales flat to down low single digits, primarily due to a decline from the $1,854 (3)% - (1)% two previously communicated new Electroph
Slide 15: 2026 Cash Flow Outlook
2026 Cash Flow Outlook ($ in millions) Cash Flow From Ops Free Cash Flow Net Total Debt Leverage CAPEX Strategic Target: $105 $95 - $105 2.5x - 3.5x $91 $205 $1,185 - $196 $185 - $205 $1,190 $1,205 $954 3.0x 2.5x - 3.5x $100 $105 $85 - $105 2.6x 2024 2025 2026 2024 2025 2026 YE24 YE25 YE26 YE24 YE25
Slide 16: Wrap-Up
Wrap-Up O Integer’
Slide 17: Summary
Summary 1Q organic sales up 1%, in 1Q26 financial results in line with February outlook line with February outlook • Organic sales up 1% versus the prior year, impacted primarily by expected headwinds from the three new products • Adjusted operating income margin declined 230bps, driven primarily by
Slide 18: Questions?
Questions?
Slide 19: Appendix
Appendix O Integer’
Slide 20: Acronym Reference Guide
Acronym Reference Guide AOI Adjusted operating income C&V Cardio & Vascular Change Change on a year-over-year basis, unless otherwise noted CRM Cardiac Rhythm Management CRM&N Cardiac Rhythm Management & Neuromodulation EBITDA Earnings Before Interest, Taxes, Depreciation & Amortization EPS Earnings
Slide 21: 2026 Financial and Supplemental Financial Outlook
2026 Financial and Supplemental Financial Outlook ($ in millions, except per share amounts) 2026 Outlook(a) Supplemental Financial Outlook ITGR: 1Q26 Earnings Conference Call April 30, 2026 | 21
Slide 22: Capitalization
Capitalization ($ in millions) 4/3/26 4/3/26 As Reported Rate Cash & Cash Equivalents $8 USD Denominated Revolver [Due 2028] $65 SOFR + 125bps EUR Denominated Revolver [Due 2028] - EURIBOR + 125bps TLA [Due 2028] $91 SOFR + 125bps Convertible Bonds [Due 2028] $116 2.125% fixed Convertible Bonds [Due
Slide 23: Historical Financial Results
Historical Financial Results ($ in millions, except per share amounts) Sales Adjusted EPS $1.79 $1.76 $476 $468 $472 $449 $437 $18 $440 $428 $431 $21 $21 $1.55 $408 $25 $24 $18 $10 $1.43 $1.43 $28 $29 $1.31 $172 $1.30 $167 $169 $1.20 $171 $160 $168 $1.14 $168 $165 $157 $287 $277 $284 $255 $259 $262
Slide 24: Product Line Review
Product Line Review O Integer’
Slide 25: Year-over-Year Sales Trend, Trailing 4 Quarters
Year-over-Year Sales Trend, Trailing 4 Quarters Integer Cardio & Vascular % of Sales (1) 17% 18% 17% 14% 13% 60% 1Q25 2Q25 3Q25 4Q25 1Q26 10% 10% 9% 8% CRM & Neuromodulation % of Sales (1) 38% 6% 37% 36% 6% 1Q25 2Q25 3Q25 4Q25 1Q26 5% 4% 1% 2% 1Q25 2Q25 3Q25 4Q25 1Q26 ITGR: 1Q26 Earnings Conference
Slide 26: Other Markets
(1) % of Sales Other Markets ($ in millions) 4% Includes products from the divested AS&O product line, the Portable Medical market exit, and other products not included in Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation Quarterly Sales Trailing 4 Quarter Sales 1Q26 sales decreased
Slide 27: Non-GAAP Financial Measures
Non-GAAP Financial Measures
Slide 28: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation may contain the non-GAAP financial measures defined in the table below. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the financial schedules accompanying the earnings releas
Slide 29: Non-GAAP Reconciliation
Non-GAAP Reconciliation 1Q26 Net Income and Diluted EPS Reconciliation – Detailed View ($ in thousands, except per share amounts) 2026 2025 GAAP Non-GAAP Non-GAAP Restructuring and Amortization of restructuring-related Acquisition and Other general (Gain) Loss on equity As Reported intangibles charg
Slide 30: Contact Information
Contact Information Kristen Stewart, CFA Director, Investor Relations kristen.stewart@integer.net (M) 551.337.3973 www.integer.net